<DOC>
	<DOCNO>NCT00056823</DOCNO>
	<brief_summary>The primary purpose study determine injection rhuFab V2 eye combination verteporfin photodynamic therapy ( PDT ) safe efficacious treatment patient age-related macular degeneration .</brief_summary>
	<brief_title>Intravitreal Injections rhuFab V2 Combination With Visudyne Subjects With Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent authorization use disclosure protect health information Age &gt; =50 year Eligibility treatment PDT use verteporfin study eye accord Visudyne ( R ) product label Treatment verteporfin anticipate expected Primary recurrent subfoveal choroidal neovascularization ( CNV ) lesion secondary AMD study eye A classic CNV component ( welldemarcated hyperfluorescence boundary early phase fluorescein angiogram ) &gt; =50 % total lesion area Total lesion size &gt; =5400 um great linear dimension ( GLD ) Best correct visual acuity , use ETDRS chart , 20/40 20/320 ( Snellen equivalent ) study eye Treatment verteporfin study eye le 3 month precede Day 0 Treatment verteporfin nonstudy eye le 7 day precede Day 0 More three prior treatment verteporfin PDT study eye within 12 month precede Day 0 Prior treatment externalbeam radiation therapy transpupillary thermotherapy study eye Previous participation clinical trial ( either eye ) involve antiangiogenic drug ( pegaptanib , rhuFab V2 , anecortave acetate , protein kinase C inhibitor , etc . ) Previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye Previous subfoveal focal laser photocoagulation study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede Day 0 History vitrectomy , submacular surgery , surgical intervention AMD study eye Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral study ) Subretinal hemorrhage study eye involve center fovea , size hemorrhage either &gt; =50 % total lesion area &gt; =1 disc area size Subfoveal fibrosis atrophy study eye Clinical angiographic evidence retinal angiomatous proliferation study eye , also angiographic evidence classic CNV CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Retinal pigment epithelium tear involve macula study eye Any concurrent intraocular condition ( e.g. , cataract diabetic retinopathy ) , opinion investigator , either could require medical surgical intervention 24month study period prevent treat visual loss might result condition , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity 24month study period Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye . Infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye Spherical equivalent refractive error study eye demonstrate 8 diopter myopia Intraocular surgery ( include cataract surgery ) study eye within 1 month precede Day 0 Uncontrolled glaucoma study eye ( defined intraocular pressure &gt; =30 mmHg despite treatment antiglaucoma medication ) Premenopausal woman use adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . Current treatment active systemic infection Contraindications verteporfin photodynamic therapy ( determined investigator ) History allergy fluorescein , amenable treatment Inability dilate pupil &gt; =6 mm diameter Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>AMD</keyword>
</DOC>